FreeTheAI

Entrada Therapeutics Reports Phase 1/2 DMD Trial Results as Shares Fall

MixedMedium impact
TRDA$4.86 −11.64%

Entrada Therapeutics, Inc. (TRDA) announced initial positive data from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45 in patients with Duchenne muscular dystrophy who are amenable to exon 45 skipping. The first group of participants met primary safety and tolerability goals at a starting dose of 5 mg/kg, showing a mean dystrophin increase of 0.10% and an exon skipping increase of 0.15% from baseline.

The trial tests an investigational therapy designed for administration once every six weeks, which could reduce dosing frequency to approximately nine infusions per year compared to current weekly regimens. Dystrophin is an essential protein for maintaining muscle cell integrity, and restoring its production is a key goal in Duchenne treatment. Despite meeting primary trial objectives, shares of the biopharmaceutical company fell 11.64% to $4.86.

All participants from Cohort 1 have progressed into an open-label Phase 2 extension. Enrollment for Cohort 2 testing a 10 mg/kg dose is complete, with data expected in the first half of 2027. Entrada Therapeutics plans to escalate dosing up to 15 mg/kg in Cohort 3 to test for higher dystrophin production and functional benefits.

Key points

  • Entrada Therapeutics reported that Cohort 1 of its Phase 1/2 ELEVATE-45-201 study met primary safety and tolerability goals at a 5 mg/kg dose.
  • Treated participants demonstrated a 0.10% mean increase in dystrophin production and a 0.15% mean increase in exon skipping.
  • ENTR-601-45 is designed for dosing once every six weeks, offering potential for nine annual infusions rather than weekly treatments.
  • Data from Cohort 2 evaluating a 10 mg/kg dose is expected in the first half of 2027, with plans to test up to 15 mg/kg in Cohort 3.
  • Shares of Entrada Therapeutics fell 11.64% to $4.86 following the trial update.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the trial results for Entrada Therapeutics ENTR-601-45?

Cohort 1 of the Phase 1/2 study met safety and tolerability goals at a 5 mg/kg dose. Treated patients achieved a 0.10% mean increase in dystrophin production and a 0.15% mean increase in exon skipping compared to baseline.

How often is ENTR-601-45 administered?

ENTR-601-45 is designed to be administered once every six weeks, or roughly nine times per year, compared to current standard weekly infusions for Duchenne muscular dystrophy.

When will Entrada Therapeutics report the next trial data?

Entrada Therapeutics expects to report topline data from Cohort 2 evaluating a 10 mg/kg dose in the first half of 2027, followed by data from Cohort 3 at doses up to 15 mg/kg.